Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 2Phase 1/2 2

Status

Unknown 3Terminated 2Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 9OTHER 7

Study Type

Interventional 7

Sponsor

Cancer Type

Breast 7

Conditions

Breast Neoplasms 272Carcinoma, Non-Small-Cell Lung 195Prostatic Neoplasms 171Stomach Neoplasms 100Lung Neoplasms 93Squamous Cell Carcinoma of Head and Neck 74Head and Neck Neoplasms 69Esophageal Neoplasms 56Neoplasms 47Neoplasm Metastasis 36Pancreatic Neoplasms 31Nasopharyngeal Carcinoma 30Ovarian Neoplasms 27Sarcoma 26Urinary Bladder Neoplasms 25Triple Negative Breast Neoplasms 20Adenocarcinoma 19Carcinoma, Squamous Cell 17Adenocarcinoma Of Esophagus 17Esophageal Squamous Cell Carcinoma 16Carcinoma, Ovarian Epithelial 15Unspecified Adult Solid Tumor, Protocol Specific 13Carcinoma, Transitional Cell 13Breast Neoplasms, Male 13Adenocarcinoma of Lung 12Salivary Gland Neoplasms 11Laryngeal Neoplasms 11Small Cell Lung Carcinoma 10Inflammatory Breast Neoplasms 10Uterine Cervical Neoplasms 9

Interventions

Trastuzumab 20pyrotinib 14pertuzumab 8Paclitaxel 7Docetaxel 7Capecitabine 4Protons 3Carboplatin 3neratinib 2Neoadjuvant Therapy 2Fulvestrant 2Cyclophosphamide 2Ado-Trastuzumab Emtansine 2tucatinib 1trastuzumab deruxtecan 1pegfilgrastim 1palbociclib 1inavolisib 1exemestane 1envafolimab 1dalpiciclib 1atezolizumab 1Taxoids 1Metformin 1Leuprolide 1Letrozole 1Isovaleryl-CoA Dehydrogenase 1Goserelin 1Genetic Testing 1Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
OTHER × HER2-positive Breast Cancer × Docetaxel × Clear all
NCT04419181 2025-10-14

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

University of Rochester

Phase 2 Withdrawn
Breast

HER2-positive Breast Cancer

NCT05426486 2024-10-30

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Shengjing Hospital

Phase 2/3 Active not recruiting
136 enrolled
Breast

HER2-positive Breast Cancer

NCT05189067 2022-01-12

Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2/3 Unknown
190 enrolled
Breast

HER2-positive Breast Cancer

NCT03238495 2021-12-07

HERMET

University of Kansas Medical Center

Phase 2 Unknown
100 enrolled
Breast

HER2-positive Breast Cancer

NCT04034823 2019-07-26

KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Unknown
59 enrolled
Breast

HER2-positive Breast Cancer

NCT02379585 2018-04-24

STEFNE

Western Regional Medical Center

Phase 1/2 Terminated
8 enrolled 1 chart
Breast

HER2-positive Breast Cancer

NCT02345772 2018-02-20

Neohttp

Western Regional Medical Center

Phase 1/2 Terminated
4 enrolled 1 chart
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡